Q3216555 (Q3216555): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en) |
(Changed an Item: Edited by the infer coords bot - inferring coordinates from location) |
||||||||||
| Property / coordinate location | |||||||||||
41°32'21.66"N, 2°12'47.12"E
| |||||||||||
| Property / coordinate location: 41°32'21.66"N, 2°12'47.12"E / rank | |||||||||||
Normal rank | |||||||||||
Revision as of 17:13, 10 October 2021
Project Q3216555 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3216555 in Spain |
Statements
12,216,906.0 Euro
0 references
24,433,812.0 Euro
0 references
50.0 percent
0 references
30 July 2015
0 references
30 July 2018
0 references
INSTITUT UNIVERSITARI DE CIENCIA I TECNOLOGIA SA
0 references
41°32'21.66"N, 2°12'47.12"E
0 references
08124
0 references
El núcleo de alto rendimiento en investigación de nuevos fármacos para el sistema inmune (N-H2L-Im) pretende sintetizar e identificar candidatos novedosos, que posteriormente se puedan desarrollar como nuevos fármacos en el área inmune, dado que los compuestos de referencia, ciclosporina A y tacrolimus, piedra angular de las terapias inmunosupresoras, no son selectivos y provocan efectos secundarios muy graves derivados de una administración prolongada, como neurotoxicidad, disfunción renal, hipertensión, diabetes... Los efectos secundarios graves de estos fármacos, ambos inhibidores de calcineurina (CN - fosfatasa dependiente de calcio y calmodulina, clave en la regulación, entre otros, de la respuesta inmune), se han asociado al secuestro de las inmunofilinas celulares, que dejan de ejercer su papel fisiológico, y a la inhibición de la actividad fosfatasa de CN sobre todos sus sustratos. Por lo tanto, la obtención de un compuesto capaz de inhibir CN sobre los NFAT de una manera específica podría llevar asociada un menor número de efectos secundarios. Este es el objetivo del proyecto. (Spanish)
0 references
The High-Performance Hub for New Immune System Drug Research (N-H2L-Im) aims to synthesize and identify novel candidates, which may later be developed as new drugs for the immune system, since the reference compounds, Ciclosporin A and tacrolimus, the cornerstone of immunosuppressive therapies, are not selective and can cause very severe side effects from prolonged administration, such as neurotoxicity, kidney dysfunction, hypertension, and diabetes. The severe side effects of these drugs, which are both inhibitors of calcineurin (a phosphatase dependent on calcium and calmodulin that is a key regulator of the immune response and other processes), have been linked to the sequestration of cellular immunophilins that no longer perform their physiological function, and the inhibition of calcineurin phosphatase activity on all its substrates. Therefore, a compound that specifically inhibits calcineurin phosphatase activity in NFATs could reduce the side effects. Obtaining this compound is the objective of the project. (English)
0 references
Mollet del Vallès
0 references
Identifiers
IU70-005487
0 references